Nuron Biotech, Inc., an Exton, PA-based specialty biologics and vaccines company, closed an $80m financing.
The financing, provided by new investor HealthCare Royalty Partners II, LP, included a $30m equity investment and a $50m Synthetic Royalty® agreement tied to future sales of Meningitec™, HibTITER® and the company’s other products, including NU100.
Led by Shankar Musunuri, Ph.D., MBA, Chief Executive Officer and Founder, Nuron is developing novel biologics and vaccines for the prevention and treatment of neurodegenerative and infectious diseases.
The company now intends to use the proceeds to commercialize and expand Meningitec™, recently acquired from Pfizer Inc., an established commercial vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C, as well as to support the clinical development of its novel biologics and vaccines for infectious and neurodegenerative diseases, including HibTITER® and NU100, a multiple sclerosis treatment.
FinSMEs
26/12/2012